North Dakota State Investment Board Sells 15,795 Shares of Illumina, Inc. $ILMN

Key Points

• North Dakota State Investment Board cut its Illumina stake by 77.2% in the third quarter, selling 15,795 shares and retaining 4,653 shares valued at approximately $1.27 million.
• Institutional investors own 89.42% of Illumina, while insiders have sold more than 2 million shares worth approximately $436.4 million over the past 90 days.
• Illumina exceeded quarterly EPS expectations and reported 4.2% year-over-year revenue growth, but analyst sentiment remains cautious: the stock carries a consensus “Hold” rating with an average price target of $238.53.

North Dakota State Investment Board lowered its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 77.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,653 shares of the life sciences company's stock after selling 15,795 shares during the period. North Dakota State Investment Board's holdings in Illumina were worth $1,273,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Illumina during the second quarter valued at approximately $3,374,423,000. WCM Investment Management LLC boosted its holdings in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA acquired a new position in Illumina in the second quarter worth approximately $617,981,000. Janus Henderson Group PLC grew its position in Illumina by 1.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company's stock worth $258,924,000 after buying an additional 29,094 shares during the last quarter. Finally, Southpoint Capital Advisors LP grew its position in Illumina by 20.0% in the first quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company's stock worth $258,846,000 after buying an additional 349,536 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Insiders Place Their Bets

In other Illumina news, Director Keith Meister sold 457,858 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares of the company's stock, valued at $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 2,061,235 shares of company stock worth $436,356,102. Insiders own 2.90% of the company's stock.

Illumina Stock Performance

Shares of ILMN opened at $235.99 on Friday. The company has a 50-day moving average of $249.30 and a two-hundred day moving average of $176.18. The stock has a market cap of $35.63 billion, a price-to-earnings ratio of 40.62, a PEG ratio of 4.11 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina, Inc. has a one year low of $106.12 and a one year high of $309.35.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 29.41%. The firm's revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.34 earnings per share. On average, equities research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Citigroup upped their price target on Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft downgraded Illumina to a "hold" rating in a research report on Wednesday, August 5th. Stephens lowered Illumina from an "overweight" rating to an "equal weight" rating and set a $275.00 price objective for the company. in a research note on Friday, October 23rd. Barclays boosted their target price on Illumina from $160.00 to $200.00 and gave the stock an "underweight" rating in a research report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. cut their target price on Illumina from $320.00 to $300.00 and set an "overweight" rating on the stock in a research report on Friday. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Illumina has a consensus rating of "Hold" and an average target price of $238.53.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.